Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

496 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Abrupt onset of Sweet syndrome, pityriasis rubra pilaris, pityriasis lichenoides et varioliformis acuta and erythema multiforme: unravelling a possible common trigger, the COVID-19 vaccine.
Sechi A, Pierobon E, Pezzolo E, Germi L, Trevisan G, Zardo D, Riva G, Mondino S, Naldi L. Sechi A, et al. Among authors: naldi l. Clin Exp Dermatol. 2022 Feb;47(2):437-440. doi: 10.1111/ced.14970. Epub 2021 Oct 21. Clin Exp Dermatol. 2022. PMID: 34617317 Free PMC article. No abstract available.
Erythrodermic psoriasis improved by Tildrakizumab.
Trevisan G, Germi L, Naldi L. Trevisan G, et al. Among authors: naldi l. Dermatol Reports. 2022 Nov 23;14(4):9448. doi: 10.4081/dr.2022.9448. eCollection 2022 Nov 21. Dermatol Reports. 2022. PMID: 36483225 Free PMC article.
Long-term drug survival of dupilumab and associated predictors in moderate-to-severe atopic dermatitis: A real-world prospective cohort study.
Pezzolo E, Rossi M, Caroppo F, Bianchelli T, Belloni Fortina A, Giacchetti A, Calzavara Pinton P, Naldi L. Pezzolo E, et al. Among authors: naldi l. J Eur Acad Dermatol Venereol. 2023 Jun;37(6):e757-e759. doi: 10.1111/jdv.18889. Epub 2023 Feb 6. J Eur Acad Dermatol Venereol. 2023. PMID: 36662631 No abstract available.
Survival, efficacy and safety of tralokinumab after 32 and 52 weeks of treatment for moderate-to-severe atopic dermatitis in adults: A multicentre real-world study.
Pezzolo E, Schena D, Gambardella A, Rossi M, Barei F, Calzavara Pinton P, Girolomoni G, Naldi L, Ferrucci SM. Pezzolo E, et al. Among authors: naldi l. J Eur Acad Dermatol Venereol. 2024 Jan;38(1):e11-e13. doi: 10.1111/jdv.19382. Epub 2023 Aug 1. J Eur Acad Dermatol Venereol. 2024. PMID: 37483150 No abstract available.
496 results